Edwards Lifesciences sees FY24 adjusted EPS $2.70-$2.80, consensus $2.80

Sees FY24 revenue $6.3B-$6.6B, consensus $6.51B. Sees FY24 free cash flow $1.1B-$1.4B. Sees FY24 tax rate 14%-17%. Sees FY24 operating margin 29%-30%. “We expect our sharpened focus in structural heart to drive sustainable growth in the years to come as we embark on a new era of innovation to address large unmet patient needs,” said Bernard Zovighian, Edwards’ CEO. “I’m pleased with our performance in 2023 as we have reinforced our TAVR leadership position with new clinical evidence and reached an inflection point with new approved mitral and tricuspid technologies. In 2024, we are projecting strong sales growth and look forward to launching breakthrough technologies and progressing on multiple important clinical trials.”